Bills, bills, bills

Expanding fintech company bets on Houston for second office

California-based Bill.com is opening its second office in Houston. Photo via Bill.com

Usually, getting stuck with the bill isn't a good situation to be in, but this is different. Houston just scored the second office of Bill.com, a Palo Alto, Calif.-based business software company. The company decided on Houston because of what the city has to offer both the business and its employees.

"We conducted an extensive national search to select our first location outside the San Francisco Bay Area," says René Lacerte, CEO of Bill.com, in a release from the Greater Houston Partnership. "We're growing at a high speed and it's critical to find the right mix of talent, quality of life and business-friendliness in our next office location. We found all this and more in Houston and are delighted the city can support our next phase of growth."

Planned to open this spring, Bill.com's Houston office will be located on the west side of town at the CityWest development, where it will occupy 25,000 square feet, per the release, and employ 125 people.

"The City of Houston is thrilled to welcome the Bill.com team," says Houston Mayor Sylvester Turner in the release. "We've always been a global and innovative city and the Bill.com announcement is another great example of Houston's building momentum as a leading digital tech hub. We offer a great place to live, work and grow a business, especially for startups and entrepreneurs."

Bill.com was founded in 2006 by René Lacerte and has raised over $259 million in funding. The software-as-a-service company has over 3 million members, according to Bill.com, and processes $60 billion in payments annually.

The Greater Houston Partnership was instrumental in bringing the second Bill.com office to town.

"Houston has always been at the cutting edge of technology — we put a person on the moon and created the first artificial heart, and we continue to build on that legacy," says Susan Davenport, the Greater Houston Partnership's chief economic development officer. "We've been working hard over the last couple of years to develop our community as a hub for digital tech, and the Bill.com expansion here is a validation and confirmation that we've made great progress."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted